Medicine Matters: The Springer Medicine Podcast

Since its discovery in 2020, great strides have been made in understanding and managing VEXAS syndrome. Listen to Dr. Peter Grayson as he shares his insights and hopes.

How does air pollution impact cardiovascular health? Dr. Anusha Seneviratne outlines the mechanisms, epidemiological evidence, and preventive measures.

Take a deep dive into the rapidly evolving world of therapeutic cancer vaccines with Dr. Elias Sayour and find out why he is so excited about upcoming developments.

The Chief Editors of Nature Reviews Cardiology, Endocrinology, and Rheumatology join us to chat about the exciting advances that caught their attention in 2025.

Prof. Edoardo Savarino takes us through the updated UEG and ESNM dysphagia guidelines and the difference they could make to patient outcomes.

We reflect on a key breakthrough in the treatment of CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.

We talk to Prof. Messoud Ashina about PACAP signaling and why targeting it might be the next big breakthrough for sustained migraine control.

Dr. Hamish Mohammed discusses the rollout of the world’s first vaccination program against gonorrhea.

We talk with Prof. Daniel Drucker about the early work on GLP-1 medicines for the treatment of diabetes, how they are now impacting the lives of people living with obesity, and their potential use for many other indications.

Dr. Annegret Dahlmann-Noor explores why the number of children and adolescents with myopia is increasing and what we can do to halt the trend.

Prof. Ali Mobasheri identifies the key issues in developing a successful DMOAD and how they can be overcome.

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

We talk to Dr. Cristina Saura about the concerns around breastfeeding after a breast cancer diagnosis, and why the POSITIVE results are such good news.

Dr. Nicolas Villain outlines why it is so important to consider both clinical symptoms and biological findings when diagnosing Alzheimer's disease.

Prof. Vlad Ratziu discusses the updated subclassification and nomenclature for steatotic liver disease, the therapeutic advance of resmetirom, and the future for MASLD and MASH.

Prof. Giacomo Grasselli takes us through the new concepts and explains why defining ARDS is such a difficult proposition.

Dr. Eduard Shantsila discusses rehabilitation approaches for complex patients with heart disease and comorbid frailty, including those with cognitive vulnerability.

Prof. Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.

Prof. Marion Subklewe explores the interplay between the gut microbiota and the efficacy and safety of CAR T-cell therapy in people with hematologic malignancies.

Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists in predicting patients’ clinical outcomes after stroke.

A conversation with Dr. Luis Paz-Ares about the key questions raised by the ADAURA trial of adjuvant osimertinib in early-stage NSCLC.

Drs Niels Holm and Lene Andreasen explore the latest data on OCT and discuss its potential as an effective approach in PCI.

Professor Andrew Beggs discusses best practice in the use of next-generational sequencing within thyroid and non-small cell lung cancers. This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company

Prof. Malin Parmar explains why stem cell therapy is such a good option for patients with Parkinson’s disease and how its safety is being tested in the STEM-PD trial.

Professors Morris Brown and Bryan Williams join Jane Godsland to explore the theories behind resistant hypertension, and the latest treatment approaches.